文献速递眼底病与葡萄膜炎

玻璃体切除术与阿柏西普治疗糖尿病视网膜病变玻璃体出血的视觉 acuity 及其他眼部结局:随机临床试验二次分析

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该事后分析基于一项随机临床试验,纳入205只因增殖性糖尿病视网膜病变(PDR)相关玻璃体出血导致视力下降且考虑行玻璃体切除术的患眼,比较初始阿柏西普注射与玻璃体切除联合全视网膜光凝(PRP)的探索性结局。

要点

  • 基线视力差于20/800的患眼,初始玻璃体切除联合PRP在24周内视力恢复更快。
  • 全队列中玻璃体切除组玻璃体出血清除中位时间4周,显著快于阿柏西普组的36周。
  • 每组约三分之一患眼在随访中接受了替代治疗,可能影响治疗决策。

核心结论

  • 初始阿柏西普与玻璃体切除联合PRP均为PDR相关玻璃体出血的可行治疗方案。
  • 基线视力差于20/800的患眼,初始玻璃体切除联合PRP在24周内视力恢复更快。

研究设计与样本

  • 该研究为随机临床试验的事后分析,纳入205只因PDR相关玻璃体出血导致视力下降且考虑行玻璃体切除术的患眼。
  • 受试者随机接受每月4次阿柏西普注射或玻璃体切除联合PRP,两组均可依据方案标准在随访中接受替代治疗。

主要发现

  • 基线视力20/32至20/160的89只患眼中,阿柏西普组与玻璃体切除组24周视力字母评分调整平均差异为-4.3(95%CI -10.6至1.9)。

关键数值与推荐

  • 基线视力差于20/800的患眼,初始玻璃体切除联合PRP在24周内视力恢复更快。
  • 玻璃体切除联合PRP的玻璃体出血清除速度显著快于初始阿柏西普注射。

临床怎么用

  • 对于PDR相关玻璃体出血,初始阿柏西普与玻璃体切除联合PRP均可选择。
  • 基线视力差于20/800的患眼,可考虑初始玻璃体切除联合PRP以加快视力恢复和出血清除。
  • 治疗决策需考虑约三分之一患眼在随访中接受替代治疗的可能性。

局限性

  • 该研究为事后分析,探索性结局需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic retinopathy (PDR), post hoc analyses may influence treatment choices. OBJECTIVE: To compare exploratory outcomes between treatment groups that may affect treatment choices for patients with vitreous hemorrhage due to PDR. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial conducted at 39 DRCR Retina Network sites included adults with vision loss due to PDR-related vitreous hemorrhage for whom vitrectomy was considered. Data were collected from November 2016 to January 2020. INTERVENTIONS: Random assignment to 4 monthly injections of aflibercept vs vitrectomy with PRP. Both groups could receive aflibercept or vitrectomy during follow-up based on protocol-specific criteria. MAIN OUTCOMES AND MEASURES: Visual acuity area under the curve (adjusted for baseline VA) and clearance of vitreous hemorrhage. RESULTS: A total of 205 eyes were included in the analysis (115 male [56%] and 90 [44%] female participants; mean [SD] age, 57 [11] years). Among 89 eyes with a baseline VA of 20/32 to 20/160 (47 receiving aflibercept, including 4 [9%] that had undergone vitrectomy; 42 undergoing vitrectomy, including 3 [7%] that had received aflibercept), the adjusted mean difference in VA letter score over 24 weeks between the aflibercept and vitrectomy groups was -4.3 (95% CI, -10.6 to 1.9) compared with -16.7 (95% CI, -24.4 to -9.1) among 59 eyes with baseline VA worse than 20/800 (P = .02 for interaction; 26 in the aflibercept group, including 6 [23%] that had undergone vitrectomy; 33 in the vitrectomy group, including 8 [24%] that had received aflibercept). In the full cohort, the median time to clearance of the initial vitreous hemorrhage was 36 (interquartile range [IQR], 24-52) weeks in the aflibercept group vs 4 (IQR, 4-4) weeks in the vitrectomy group (difference, 32 [95% CI, 20-32] weeks; P < .001). CONCLUSIONS AND RELEVANCE: Both initial aflibercept and vitrectomy with PRP are viable treatment approaches for PDR-related vitreous hemorrhage. Although this study did not find a significant difference between groups in the primary outcome of mean VA over 24 weeks of follow-up, eyes receiving initial vitrectomy with PRP had faster recovery of vision over 24 weeks when baseline VA was worse than 20/800 and faster vitreous hemorrhage clearance. Approximately one-third of the eyes in each group received the alternative treatment (aflibercept or vitrectomy with PRP). These factors may influence treatment decisions for patients initiating therapy for PDR-related vitreous hemorrhage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02858076.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Glassman AR, Beaulieu WT, Maguire MG, et al. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 33956075. doi:10.1001/jamaophthalmol.2021.1110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。